Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 drive the development of gliomas, which occur in most low-grade gliomas and secondary high-grade gliomas, and they enable the isocitrate dehydrogase (NADP+) activity (Geisbrecht and Gould, 1999; Haddock et al., 2022). The gene discussed is IDH2; the disease is central nervous system cancer.